“We have continued to make progress with our patient enrollment efforts in the BPX-601 and BPX-603 trials and I am pleased with our execution,” said
Program Highlights and Current Updates
BPX-601GoCAR-T®
- Enrollment is ongoing in the dose escalation portion of the Phase 1/2 clinical trial for BPX-601 in patients with metastatic castration-resistant prostate cancer (mCRPC). Bellicum plans to present an interim data update on BPX-601 in the first quarter of 2023.
BPX-603GoCAR-T®
- Enrollment is ongoing in the dose escalation portion of the Phase 1/2 clinical trial for BPX-603 in patients with solid tumors that express human epidermal growth factor 2 (HER2), including breast, endometrial, ovarian, gastric, and colorectal cancers. Bellicum plans to present an interim data update on BPX-603 in the first half of 2023.
Financial Results for the Second Quarter 2022
R&D Expenses: Research and development expenses were
G&A Expenses: General and administrative expenses were
Loss from Operations: Bellicum reported a loss from operations of
Net Loss: Bellicum reported a net loss of
Shares Outstanding: As of
Cash Position: Bellicum reported cash and cash equivalents and restricted cash totaling
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as “continue,” “designed,” “expects,” “plans,” “intends,” “may,” “will” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Bellicum’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing of data updates from Bellicum’s ongoing BPX-601 and BPX-603 clinical trials. Various factors may cause differences between Bellicum’s expectations and actual results, including, among others, the impact of the COVID-19 pandemic on Bellicum’s clinical trial sites and trial enrollment, other factors, such as safety issues, may impact Bellicum’s clinical progress, actual expenses incurred may be higher than anticipated, and trial results may be different than anticipated, as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the
Source:
Investors:
Managing Director,
858-356-5932
robert.uhl@westwicke.com
Consolidated Balance Sheets | |||||
(Unaudited; in thousands) | |||||
2022 | 2021 | ||||
Current Assets: | |||||
Cash and cash equivalents | $ | 33,168 | $ | 46,156 | |
Restricted cash | 1,503 | 1,501 | |||
Accounts receivable, interest and other receivables | 209 | 205 | |||
Prepaid expenses and other current assets | 1,706 | 1,269 | |||
Other Assets: | |||||
Property and equipment, net | 18 | 12 | |||
Total assets | $ | 36,604 | $ | 49,143 | |
Current Liabilities: | |||||
Accounts payable | $ | 399 | $ | 90 | |
Accrued expenses and other current liabilities | 2,245 | 3,849 | |||
Warrant derivative liability | 1,887 | 2,773 | |||
Preferred stock | 18,036 | 18,036 | |||
Total stockholders' equity | 14,037 | 24,395 | |||
Total liabilities, preferred stock and stockholders' equity | $ | 36,604 | $ | 49,143 | |
Consolidated Statements of Operations | ||||||||||||||||
(Unaudited; in thousands, except share and per share amounts) | ||||||||||||||||
Three months ended | Six months ended | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Revenues: | ||||||||||||||||
Supply agreement | $ | - | $ | 700 | $ | - | $ | 700 | ||||||||
Total revenues | - | 700 | - | 700 | ||||||||||||
Operating Expenses: | ||||||||||||||||
Research and development | 5,089 | 6,722 | 9,575 | 13,183 | ||||||||||||
General and administrative | 1,448 | 1,765 | 2,901 | 3,777 | ||||||||||||
Total operating expenses | 6,537 | 8,487 | 12,476 | 16,960 | ||||||||||||
Loss on lease termination | - | - | - | 464 | ||||||||||||
Loss from operations | (6,537 | ) | (7,787 | ) | (12,476 | ) | (16,724 | ) | ||||||||
Interest income | 13 | 8 | 27 | 18 | ||||||||||||
Interest expense | - | (1 | ) | - | (4 | ) | ||||||||||
Gain on change in fair value of warrant and private placement option liabilities | 2,523 | 5,579 | 886 | 3,242 | ||||||||||||
Other expense | - | (1 | ) | - | (1 | ) | ||||||||||
Net loss | $ | (4,001 | ) | $ | (2,202 | ) | $ | (11,563 | ) | $ | (13,469 | ) | ||||
Net loss per common share attributable to common shareholders, basic and diluted | $ | (0.13 | ) | $ | (0.22 | ) | $ | (0.38 | ) | $ | (1.34 | ) | ||||
Weighted-average shares outstanding, basic and diluted | 30,829,184 | 10,108,388 | 30,824,407 | 10,071,882 | ||||||||||||
Source:
2022 GlobeNewswire, Inc., source